Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Triple negative • Breast Cancer, Non-metastatic • Immune Checkpoint Inhibitor
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
If not, would you lean towards adjuvant capecitabine?
Answer from: Medical Oncologist at Academic Institution
In these situations, adjuvant AC should be considered. Anthracyclines have been shown to improve outcomes in high-risk TNBC in the adjuvant setting across multiple trials. CREATE-X used adjuvant capecitabine in patients who had residual disease after neoadjuvant anthracyclines and taxanes. It wasn't...
Sign in or Register to read more